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Sample-Index Misassignment 
Impacts Tumour Exome Sequencing
Daniel Vodák1,2,3, Susanne Lorenz2,3,4, Sigve Nakken  2,3, Lars Birger Aasheim2, Harald Holte2,5,6, 
Baoyan Bai6,7, Ola Myklebost  2,3,8, Leonardo A. Meza-Zepeda2,3,9 & Eivind Hovig  2,3,10,11
Sample pooling enabled by dedicated indexes is a common strategy for cost-effective and robust 
high-throughput sequencing. Index misassignment leading to mutual contamination between pooled 
samples has however been described as a general problem of the latest Illumina sequencing instruments 
utilizing exclusion amplification. Using real-life data from multiple tumour sequencing projects, we 
demonstrate that index misassignment can induce artefactual variant calls closely resembling true, 
high-quality somatic variants. These artefactual calls potentially impact cancer applications utilizing 
low allelic frequencies, such as in clonal analysis of tumours. We discuss the available countermeasures 
with an emphasis on improved library indexing methods, and provide software that can assist in the 
identification of variants that may be consequences of index misassignment.
Identification of somatic variants by next-generation sequencing has become an important technique in cancer 
research by pinpointing the genomic causes of tumour phenotypes. An increasing number of examples have 
further shown that genomic aberrations have prognostic value and can inform rational clinical deployment of tar-
geted cancer drugs1,2. As of now, next-generation sequencing technologies enable affordable assaying of variation 
in the entire tumour genome within days, but despite the availability of specialized software tools, somatic variant 
calling continues to pose challenges. Notably, the inherent complexity of tumours, as exemplified by aneuploidy, 
tumour heterogeneity, and sample impurity, often leads to important somatic variants only being detectable in low 
allelic fractions (AFs)3–7. AFs can be further affected due to technical reasons, such as the inability to accurately 
represent allelic ratios at genomic loci with low coverage8. As a consequence of the necessarily high required sen-
sitivity, somatic variant calling is susceptible to random noise, systematic artefacts, and sample contamination9,10. 
When unnoticed, false positive variant calls can contribute to high costs incurred by follow-up analyses and 
experiments, and in the worst case support inadequate therapeutic strategies.
As previously described in the context of RNA-seq applications11, when material from multiple samples is 
being pooled together before sequencing, the sequencing technology itself can be a source of noticeable sam-
ple cross-contamination. Sample pooling (also called sample multiplexing) is a standard means of dividing 
the throughput of a sequencing instrument among multiple samples, relying on index sequences that uniquely 
barcode the material of each involved sample. Sample index misassignment, a phenomenon most evident on 
Illumina instruments utilizing exclusion amplification chemistry (ExAmp) and patterned flow cell technology 
(i.e., HiSeq 3000/4000/X Ten and NovaSeq), effectively leads to transfer of individual sequencing reads between 
samples included into a common pool11.
Our analysis of high-coverage tumour sequencing data shows that index misassignment is a source of false 
positive somatic variant calls in a form of true variation obtained from co-multiplexed samples.
1Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. 2Norwegian Cancer Genomics 
Consortium, Institute for Cancer Research, The Norwegian Radium Hospital/Oslo University Hospital, Oslo, 
Norway. 3Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital/Oslo 
University Hospital, Oslo, Norway. 4Department of Core Facilities, Institute for Cancer Research, The Norwegian 
Radium Hospital/Oslo University Hospital, Oslo, Norway. 5Department of Oncology, Cancer Clinic, Oslo University 
Hospital, Oslo, Norway. 6Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway. 7Department of Cancer 
Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. 8Department of Clinical Science, 
University of Bergen, Bergen, Norway. 9Genomics Core Facility, Department of Core Facilities, Institute for Cancer 
Research, The Norwegian Radium Hospital/Oslo University Hospital, Oslo, Norway. 10Department of Cancer Genetics 
and Informatics, Oslo University Hospital, Oslo, Norway. 11Department of Informatics, University of Oslo, Oslo, 
Norway. Leonardo A. Meza-Zepeda and Eivind Hovig contributed equally to this work. Correspondence and requests 
for materials should be addressed to E.H. (email: ehovig@ifi.uio.no)
Received: 21 November 2017
Accepted: 15 March 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIENTIFIC REpoRTS |  (2018) 8:5307  | DOI:10.1038/s41598-018-23563-4
Results
We investigated tumour-normal sample pairs of three different tumour types: diffuse large B-cell lymphoma, 
follicular lymphoma, and sarcoma. All samples were collected from cancer patients in Norway, and deep exome 
sequencing (median coverages: 315X for tumour samples, 146X for controls) was carried out on local Illumina 
instruments: three HiSeq 2000/2500 instruments utilizing bridge amplification (generating 42 diffuse large B-cell 
lymphoma samples and 31 sarcoma samples) and a HiSeq 4000 employing ExAmp (generating 81 follicular lym-
phoma samples and 77 sarcoma samples). All samples were subject to standardized library preparation, sequenc-
ing, and bioinformatics analysis, as adopted by the Norwegian Cancer Genomics Consortium (NCGC, http://
cancergenomics.no) (Methods, Supplementary Information).
In our assessment of index misassignment, we have examined the consequences for calling of somatic sin-
gle nucleotide variants (SSNVs). For increased reliability, all tests and analyses were limited to SSNVs agreed 
upon by two independent variant callers (MuTect and Strelka)3,12. Sample-wise contamination estimates, our 
primary measure of contamination, were generated by Conpair13, based on the allelic composition on several 
thousand genomic marker sites in a given matched sample pair. Our tests on simulated data suggest that Conpair 
provides consistent quantifications, despite apparent progressive underestimation dependent on the number of 
contributing contamination sources (Supplementary Tables 1 and 2, Supplementary Information). We attribute 
this underestimation to decreasing contaminant variant AFs in sample pools of increasing size (Supplementary 
Fig. 1) paired with the fact that Conpair’s contamination model is intended for two-sample mixtures only.
A schematic overview of all conducted experiments and their data dependencies is available on Fig. 1.
Contamination rates. During the analysis of hundreds of sequenced tumour-normal matched pairs, we 
noted that data generated on the ExAmp instrument showed significantly higher sample-wise contamination lev-
els in comparison to data from bridge amplification instruments (median per-sample contamination estimates: 
0.839% vs. 0.187%, p-value < 0.001, Fig. 2a, Supplementary Fig. 2). To specifically assess the role of multiplexing 
on the ExAmp instrument, we sequenced 16 selected sample libraries both in pools and individually (i.e., one sam-
ple library per flow cell lane), observing significantly increased contamination rates in sequencing output from 
the multiplexed libraries (median per-sample contamination estimates: 0.644% vs. 0.0465%, p-value < 0.001, 
Supplementary Table 3). Removal of free adapters/primers prior to sequencing was in Illumina’s report identi-
fied as a key measure for mitigating the cross-contamination rates (https://www.illumina.com/science/education/
minimizing-index-hopping.html), but for the 16 libraries included in our testing, performing a gel-based library 
purification step in combination with bead purification did not provide improvements over bead purification alone 
(median per-sample contamination estimates: 0.671% vs. 0.6115%, p-value = 0.159). In accordance with previous 
Figure 1. A schematic overview of the three main conducted experiments. The same library material was used 
for any given sample included in multiple experiments.
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reports by Illumina and Sinha et al., we concluded that ExAmp chemistry is the cause of sample contamination. The 
dependency on sample pooling indicated that co-multiplexed samples serve as the contaminants.
Artefactual variant calls. In order to assess the impact of ExAmp-associated index misassignment on the 
detection of SSNVs, we first set out to identify SSNVs that were likely to originate from contamination. For each 
somatic variant found in a given tumour sample, we quantified the variant support in the expected source of 
contamination - the corresponding “pool complement” consisting of reads from all co-multiplexed samples from 
other individuals. We thus calculated two allelic fractions for each somatic variant: the standard sample AF and 
an AF derived from the pool complement (PC-AF) (Supplementary Fig. 3, Supplementary Information). Two 
distinct classes of variants can be identified when variant AFs and PC-AFs are plotted against each other: (1) 
apparently true somatic variants, consisting of variants not present in the Norwegian population (i.e., absent from 
NCGC’s cohort of normal samples) and lacking support in their respective pool complements (PC-AF < 0.01); 
and (2) suspected contaminant variants, consisting of common Norwegian germline variants (>  = 5% allele fre-
quency in NCGC’s cohort of normal samples) with a considerable support in their respective pool complements 
(PC-AF >  = 0.2) (Supplementary Fig. 4). We classify the remaining variants as ambiguous.
In comparison to bridge amplification, ExAmp leads to higher occurrence of SSNVs that coincide with germline 
variation common in the Norwegian population (Fig. 2b). At the same time, PC-AFs of these variants are signifi-
cantly higher in the ExAmp datasets (median values: 0.508 vs. 0.125, p-value < 0.001), showing a much better corre-
spondence to the suspected contamination source. Samples sequenced on the ExAmp instrument have significantly 
higher counts of suspected contaminant variants than samples sequenced on bridge amplification instruments 
(per-sample median counts: 4 vs. 0, p-value < 0.001) and show significant correspondence between the number of 
suspected contaminant variants and the estimated contamination (p-values < 0.001, Fig. 3).
Discussion
We have focused on exploring the general link between tumour sample cross-contamination and suspected 
contaminant variants of germline origin, but the effects of index misassignment require further consideration 
(Table 1). Firstly, cross-sample contamination by recurrent somatic variants would represent a class of potential 
false positives that would be more difficult to recognize, and may have stronger clinical implications. Concern for 
such cases of contamination gains relevance when several samples containing identical somatic variants are being 
co-multiplexed and thereby jointly contribute to elevated pool complement support (e.g., pooling serial patient 
biopsies or screening multiple samples likely to harbour identical hotspot mutations, particularly in sensitive 
analyses of high-purity samples). Secondly, when co-multiplexing tumour and control samples, false negative 
variant rates might be increased due to somatic variation contaminating the controls. Lastly, contamination rates 
within a given sample can be influenced by a combination of independent factors, such as the fraction of the pool 
that is constituted by the pool complement14 or a sample’s copy number profile - in copy number loss regions 
of high-purity tumour samples, we expect both the average AF and the number of contaminant variants to be 
increased due to the local underrepresentation of non-contaminant reads.
Several countermeasures have been suggested for the prevention of index misassignment, with sample storage 
conditions being shown by Illumina to influence the problem’s severity. Sequencing of a single sample per lane 
Figure 2. Amplification chemistry and its relationships to (a) sample contamination estimates and (b) 
variant counts and PC-AF values. All values are plotted separately for each combination of tumour type and 
amplification chemistry represented in the analysis. The colours distinguish between variants called in “high-
contamination” samples (Conpair contamination estimate >  = 0.5%) and variants coming from samples with 
“low contamination” (Conpair contamination estimate < 0.5%). BrAmp: bridge amplification; FL: follicular 
lymphoma; SARC: sarcoma; DLBCL: diffuse large B-cell lymphoma; SCV: suspected contaminant variant.
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proved to be an effective solution, which however might be too costly for many applications. Rigorous gel- or 
bead-based library purification has been strongly recommended as a means of index misassignment mitigation in 
case of sample multiplexing. However, in our experience, both purification methods appear to be insufficient even 
in combination. Dual indexing has been suggested for circumventing the problem by using sample-specific index 
pairs rather than individual indexes, enabling recognition of reads with unexpected index combinations caused 
by index misassignment14. Dual indexes are becoming a part of best practices for multiplexed libraries sequenced 
with ExAmp chemistry, but their current availability may vary depending on the applied library preparation pro-
tocol. The possible solutions therefore need to be assessed in the context of each particular project.
For data that have already been generated, suitable variant post-processing should be chosen based on the type 
of contamination artefacts relevant for given project (Table 1). Commonly used allelic fraction thresholds and 
germline variant database filters are likely to remove the majority of false positive somatic variant calls caused by 
index misassignment. However, a more discriminative filtering approach would be preferable in settings where 
sensitive detection is the priority, such as in clonal analysis. Low-AF variation can, in multiple cancer types, har-
bour markers of prognostic and therapeutic value15–17. When available, pool complement information can help 
identifying variants that are unlikely to be contamination artefacts, thereby reducing the number of potentially 
important true positive somatic variants discarded due to low AF or germline database presence. The code used 
for PC-AF calculation in our analyses is available for use in other projects (Methods). If control samples have 
been contaminated by true somatic variation, it might be necessary to adopt variant caller settings more permis-
sive to somatic allele evidence in the matched normal material.
We believe our findings to be of relevance to other cancer sequencing projects that utilize the ExAmp chem-
istry, even though the impacts of index misassignment on somatic variant calling may vary depending on the 
combination of employed sequencing instruments, library preparation protocols, and bioinformatics analyses. 
In general, we expect the effects of index misassignment to dampen as the sequencing depth decreases and the 
allelic fraction threshold for accepted somatic variants increases. On the other hand, we note that besides single 
nucleotide variants, other types of somatic variation (e.g. insertions and deletions) are likely to be affected.
Methods
Methods used for sample collection, DNA extraction, library preparation and sequencing, as well as full details of 
all bioinformatics analyses, are available in the methods section of Supplementary Information.
Bioinformatics analyses. All sequenced samples were pre-processed with BWA MEM18, Picard (http://
broadinstitute.github.io/picard/) and GATK19 tools, before performing somatic calling with MuTect and Strelka 
(only consensus calls were considered in subsequent processing and testing). All analyses were performed using 
human reference genome build b37 with an added decoy contig and corresponding variation databases.
The pool complement of each individual tumour sample was formed by reads of all co-multiplexed samples 
originating from other individuals. For each identified somatic variant in a given tumour sample, all overlap-
ping reads from the corresponding pool complement were extracted, and the pool complement allelic fraction 
(PC-AF, the fraction of reads supporting the variant within the pool complement) was calculated. Tumour 
Figure 3. Per-sample counts of apparently true somatic variants (a) and suspected contaminant variants 
(b) plotted against contamination estimates. All values, including Spearman’s rank correlation coefficients 
and their associated p-values, are plotted separately for each combination of tumour type and amplification 
chemistry represented in the analysis. The colours distinguish between “high-contamination” samples 
(Conpair contamination estimate >  = 0.5%) and samples with “low contamination” (Conpair contamination 
estimate < 0.5%). BrAmp: bridge amplification; FL: follicular lymphoma; SARC: sarcoma; DLBCL: diffuse large 
B-cell lymphoma.
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samples without a matched control and/or tumour samples failing our quality metrics thresholds (Supplementary 
Information) were excluded from the analyses of potential contamination targets, but did serve as potential con-
tamination sources in our PC-AF calculations.
For evaluating the role of multiplexing in ExAmp-associated index misassignment, tumour-normal sample 
pairs from 8 selected individuals were sequenced (i) individually (one sample per dedicated flow cell lane), (ii) in 
a pool of all 8 tumour/normal samples and (iii) in a pool of all 8 tumour/normal samples after applied gel puri-
fication. For generating contamination estimates with Conpair, the separately sequenced normal sample of each 
individual was used as a control for the five other samples of given individual.
Accuracy of Conpair contamination estimates was assessed with the help of artificially created exome-wide 
sample admixtures. Reads from multiple libraries were mixed to simulate contamination by 1, 2, 4 or 7 samples 
from as many different individuals, with the total contamination amounting to either ~2% or ~8% in each case, 
depending on the experiment. Conpair’s contamination estimates were compared to true contamination content, 
which was validated by library-specific depth of coverage calculations.
NCGC’s cohort of normal samples consisted of blood samples of 789 different individuals living in Norway. The 
samples were processed according to “Best Practices for Germline SNP & Indel Discovery in Whole Genome and 
Exome Sequence” developed by the Broad Institute, utilizing allele-specific (rather than site-specific) variant calling.
Statistics. All statistical tests were performed in R (http:/www.r-project.org) as two-tailed non-parametric 
tests (either Wilcoxon rank sum test with continuity correction or Wilcoxon signed rank test) of the identity of 
two populations. All input test data are available as Supplementary Data. R session information, utilized R com-
mands together with their outputs, as well as median and interquartile range values of all the tested distributions 
are available in the Supplementary Note. All distributions have been plotted as Supplementary Figures.
Ethics approval and consent. All patients provided informed consent. The study was approved by the 
Regional Committee for Medical and Health Research Ethics of South-East Norway (reference numbers 2014/127, 
S-06133 and 2010/1244). All experiments were performed in accordance with relevant guidelines and regulations.
Data availability. All data that support the findings of this study and that do not compromise research 
participant privacy are available as Supplementary Data. All data that may compromise research participant pri-
vacy (e.g., raw sequence data) are available for inspection upon request to the corresponding author [EH] on 
non-disclosure terms.
Code availability. Python code used for calculating PC-AF values is available at GitHub (https://github.com/
danielvo/IBPC). R code for generating Figures 2 and 3 is included in the Supplementary Note.
Contamination type
Cause (the type of co-
multiplexed samples)
Possible somatic variant 
calling artefacts
Prevalence of given contamination 




germline variants in 
a tumour sample
Any samples from 
other individuals
False positive somatic 
variants in the form of 
germline variation from 
other individuals
The most likely contamination type 
to occur;
Contamination targets are expected 
to be more affected in copy number 
loss regions*
A variant filter based on an 
appropriate germline variant 
database or a relevant panel of 
normal samples;
A filter based on PC-AF values (if 
a more discriminative solution is 
necessary)
b) Contaminant 
somatic variants in a 
tumour sample
Other tumour samples
False positive “recurrent” 
somatic variants in the 
form of somatic variation 
from other tumour 
samples – whether from 
other individual(s) or the 
same individual
Expected to be relevant in tumour 
sample pools enriched** for specific 
somatic variants;
Contamination targets are expected 
to be more affected in copy number 
loss regions*
A filter based on PC-AF values 
(non-discriminative filtering 
might lead to false negatives of 
high importance)
c) Contaminant 
germline variants in 
a control sample
Any samples from 
other individuals
False negatives/missed 
somatic variant calls – 
only concerning somatic 
variants that also occur as 
germline variants
Dependent on the occurrence of 
important variants as both germline 
and somatic in a given project’s 
setting
Review of calls not classified 
as somatic, adjustment of the 
variant caller parameters
d) Contaminant 




somatic variant calls – 
concerning all somatic 
variants
Elevated relevancy when matched 
samples are co-multiplexed;
Prevalence dependent on the 
enrichment** of potential 
contaminant variants in a given 
sample pool;
Consequences dependent on variant 
caller’s tendency to reject a somatic 
variant candidate due to evidence of 
its presence in the matched control
Review of calls not classified 
as somatic, adjustment of the 
variant caller parameters
Table 1. Overview of possible contamination types, their consequences and suitable filtering options. PC-AF: 
pool-complement allelic fraction. *Copy number loss regions of high-purity tumour samples will be especially 
affected. **The enrichment will increase together with given variant’s recurrence, as well as with purity of 
tumour samples that carry the variant.
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